Classification criteria for autoinflammatory recurrent fevers

Author:

Gattorno MarcoORCID,Hofer Michael,Federici Silvia,Vanoni Federica,Bovis Francesca,Aksentijevich Ivona,Anton Jordi,Arostegui Juan Ignacio,Barron Karyl,Ben-Cherit Eldad,Brogan Paul A,Cantarini Luca,Ceccherini Isabella,De Benedetti Fabrizio,Dedeoglu Fatma,Demirkaya Erkan,Frenkel Joost,Goldbach-Mansky Raphaela,Gul Ahmet,Hentgen Veronique,Hoffman Hal,Kallinich Tilmann,Kone-Paut Isabelle,Kuemmerle-Deschner Jasmin,Lachmann Helen J,Laxer Ronald M,Livneh Avi,Obici Laura,Ozen Seza,Rowczenio Dorota,Russo Ricardo,Shinar Yael,Simon Anna,Toplak Nataša,Touitou Isabelle,Uziel Yosef,van Gijn Marielle,Foell Dirk,Garassino Claudia,Kastner Dan,Martini Alberto,Sormani Maria Pia,Ruperto NicolinoORCID

Abstract

BackgroundDifferent diagnostic and classification criteria are available for hereditary recurrent fevers (HRF)—familial Mediterranean fever (FMF), tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), mevalonate kinase deficiency (MKD) and cryopyrin-associated periodic syndromes (CAPS)—and for the non-hereditary, periodic fever, aphthosis, pharyngitis and adenitis (PFAPA). We aimed to develop and validate new evidence-based classification criteria for HRF/PFAPA.MethodsStep 1: selection of clinical, laboratory and genetic candidate variables; step 2: classification of 360 random patients from the Eurofever Registry by a panel of 25 clinicians and 8 geneticists blinded to patients’ diagnosis (consensus ≥80%); step 3: statistical analysis for the selection of the best candidate classification criteria; step 4: nominal group technique consensus conference with 33 panellists for the discussion and selection of the final classification criteria; step 5: cross-sectional validation of the novel criteria.ResultsThe panellists achieved consensus to classify 281 of 360 (78%) patients (32 CAPS, 36 FMF, 56 MKD, 37 PFAPA, 39 TRAPS, 81 undefined recurrent fever). Consensus was reached for two sets of criteria for each HRF, one including genetic and clinical variables, the other with clinical variables only, plus new criteria for PFAPA. The four HRF criteria demonstrated sensitivity of 0.94–1 and specificity of 0.95–1; for PFAPA, criteria sensitivity and specificity were 0.97 and 0.93, respectively. Validation of these criteria in an independent data set of 1018 patients shows a high accuracy (from 0.81 to 0.98).ConclusionEurofever proposes a novel set of validated classification criteria for HRF and PFAPA with high sensitivity and specificity.

Funder

E-rare-3 project

Novartis Pharmaceuticals Corporation

Executive Agency For Health and Consumers

SOBI

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3